53As regards, last, the argument concerning interim injunctions granted by a national court prohibiting a manufacturer of generic medicines from entering the market of a medicine containing an active ingredient that is in the public domain, it must be observed that interim measures in no way prejudge the merits of an infringement action brought by the patent holder, a fortiori when, as in the main proceedings, such an injunction is granted in return for a cross‑undertaking in damages, given by that patent holder.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.